CX Institutional Sells 113 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

CX Institutional lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,119 shares of the medical research company’s stock after selling 113 shares during the quarter. CX Institutional’s holdings in Charles River Laboratories International were worth $469,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Rothschild Investment LLC raised its stake in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after buying an additional 144 shares during the period. Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $37,000. GeoWealth Management LLC raised its stake in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $48,000. Finally, Tortoise Investment Management LLC raised its stake in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 115 shares during the period. Institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the business’s stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $149.50 on Friday. The stock has a market cap of $7.34 billion, a price-to-earnings ratio of 996.67, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a 50 day moving average price of $129.05 and a 200-day moving average price of $157.39. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analysts’ expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.27 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Redburn Atlantic raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and decreased their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Mizuho decreased their target price on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 9th. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Finally, Robert W. Baird lifted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $171.85.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).